These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 11505461

  • 21. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 22. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
    Zuccotti G, Amendola A, Viganò A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podestà A, Rottoli A, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2007 Sep 17; 25(37-38):6692-8. PubMed ID: 17697730
    [Abstract] [Full Text] [Related]

  • 23. In vivo antibody response to mucosal (NASAL) and subcutaneous stimulation of influenza virus in patients with IgA nephropathy.
    Kashem A, Endoh M, Yano N, Yamauchi F, Nomoto Y, Sakai H.
    Tokai J Exp Clin Med; 1992 May 17; 17(1):23-8. PubMed ID: 1523689
    [Abstract] [Full Text] [Related]

  • 24. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 25. Dose sparing with intradermal injection of influenza vaccine.
    Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM.
    N Engl J Med; 2004 Nov 25; 351(22):2295-301. PubMed ID: 15525714
    [Abstract] [Full Text] [Related]

  • 26. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 25; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

  • 27. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness.
    Hurwitz ES, Haber M, Chang A, Shope T, Teo ST, Giesick JS, Ginsberg MM, Cox NJ.
    J Infect Dis; 2000 Oct 25; 182(4):1218-21. PubMed ID: 10979921
    [Abstract] [Full Text] [Related]

  • 28. Short communication: immunogenicity of an inactivated influenza vaccine and postvaccination influenza surveillance in HIV-infected and noninfected children and adolescents.
    Machado AA, Machado CM, Boas LS, Lopes MC, Gouvêa Ade F, Succi RC, Mendoza TR, Kanashiro TM, Machado DM.
    AIDS Res Hum Retroviruses; 2011 Sep 25; 27(9):999-1003. PubMed ID: 21284525
    [Abstract] [Full Text] [Related]

  • 29. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV, Scaramuzza A, Riboni S, Mameli C, Pariani E, Tanzi E, Zanetti A, Radaelli G.
    Vaccine; 2009 Aug 27; 27(39):5357-62. PubMed ID: 19607951
    [Abstract] [Full Text] [Related]

  • 30. Human immune responses elicited by an intranasal inactivated H5 influenza vaccine.
    Ainai A, van Riet E, Ito R, Ikeda K, Senchi K, Suzuki T, Tamura SI, Asanuma H, Odagiri T, Tashiro M, Kurata T, Multihartina P, Setiawaty V, Pangesti KNA, Hasegawa H.
    Microbiol Immunol; 2020 Apr 27; 64(4):313-325. PubMed ID: 31957054
    [Abstract] [Full Text] [Related]

  • 31. Specific antibody response after influenza immunization in systemic lupus erythematosus.
    Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D.
    J Rheumatol; 2002 Dec 27; 29(12):2555-7. PubMed ID: 12465151
    [Abstract] [Full Text] [Related]

  • 32. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children.
    Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP.
    Pediatrics; 2007 Sep 27; 120(3):e553-64. PubMed ID: 17698577
    [Abstract] [Full Text] [Related]

  • 33. Dynamics of neutralizing secretory influenza antibodies after nasal administration of the NIVGRIP trivalent influenza vaccine.
    Petrescu A, Steiner N, Trăilescu G, Teodosiu O, Mihăilescu M, Berca C.
    Virologie; 1985 Sep 27; 36(3):187-94. PubMed ID: 4071977
    [Abstract] [Full Text] [Related]

  • 34. [Safety of an influenza-split-vaccine in children].
    Schmitt-Grohé S, Banzhoff A, Klaassen B, Zielen S.
    Klin Padiatr; 2001 Sep 27; 213(6):338-42. PubMed ID: 11713714
    [Abstract] [Full Text] [Related]

  • 35. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ.
    J Infect Dis; 2008 Sep 01; 198(5):635-41. PubMed ID: 18694338
    [Abstract] [Full Text] [Related]

  • 36. Influenza immunisation in children with solid tumours.
    Chisholm J, Howe K, Taj M, Zambon M.
    Eur J Cancer; 2005 Oct 01; 41(15):2280-7. PubMed ID: 16143516
    [Abstract] [Full Text] [Related]

  • 37. Serum antibody responses after intradermal vaccination against influenza.
    Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G.
    N Engl J Med; 2004 Nov 25; 351(22):2286-94. PubMed ID: 15525713
    [Abstract] [Full Text] [Related]

  • 38. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)].
    Kuwert EK, Werner J, Scheiermann N, Pledt T.
    Zentralbl Bakteriol Orig A; 1979 Jul 25; 244(2-3):155-74. PubMed ID: 506543
    [Abstract] [Full Text] [Related]

  • 39. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y, Kedar E.
    J Med Virol; 2003 Apr 25; 69(4):560-7. PubMed ID: 12601765
    [Abstract] [Full Text] [Related]

  • 40. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
    J Med Virol; 2005 Jan 25; 75(1):130-6. PubMed ID: 15543590
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.